Cytiva introduces new cell lines to meet the challenges and increasing demand of viral vector manufacturing
- New offering contains three cell lines to comprehensively meet the objectives of various therapeutic programs and provide the ability to transition between cell lines as needs evolve
- A transient cell line that provides speed and flexibility enabling researchers to easily integrate it into their existing workflow. This cell line is paired with a new cell culture medium, HyClone prime expression designed to enhance performance. Both the cell line and corresponding media will be available soon.
- A packaging cell line that eases the screening of genes of interest while enabling efficiencies across clinical stages and assets. This cell line is available now in selected formulations.
- A producer cell line that stably integrates all four required genes for AAV production; production starts by simply adding an induction agent, no transfection is needed. This cell line is available now to be customized to each individual therapy.
April 30, 2024
Viral vector-based gene therapies hold immense promise for treating a multitude of diseases. However, their widespread adoption has been hindered by inefficient manufacturing methods and the absence of established standardized processes, resulting in high costs and limited accessibility for patients. Global life sciences leader, Cytiva, is bringing solutions to these challenges with its new ELEVECTA cell lines.
Emmanuel Abate, President Genomic Medicine, Cytiva says: “We are relentless in our pursuit of bringing life changing therapies to patients faster. To make gene therapy a realistic option for more patients, we need to be able to standardize its manufacturing. We’ve gone to the heart of the process by creating viral vector cell lines that will make a big impact to developers of gene therapies.”
Tapping into its deep expertise, the company has created three cell lines for adeno-associated virus (AAV) production. Together, the three lines comprehensively meet the distinct objectives of various therapeutic programs with the ability to transition between cell lines as needs evolve and can be paired with Cytiva’s established cell culture media offering:
Simplifies the manufacturing process and reduces costs
Using stable cell lines, such as packaging or producer cell lines, can streamline the product manufacturing process by simplifying workflows and extensively reducing raw materials, such as transfection reagent and plasmids. Consequently, stable cell lines can lead to reduced costs and faster market access for viral vector-based gene therapies.
Addresses an important quality challenge
Coming soon across all three cell lines is a genetic modification to reduce encapsidated host cell DNA (hcDNA). This impurity is a notable concern during production of viral vector-based gene therapies. Unlike other impurities, hcDNA cannot be efficiently removed through downstream processing due to its resistance to DNase treatment, posing a significant challenge not yet addressed by the industry. Cytiva has genetically engineered the ELEVECTA cell lines to minimize the presence of encapsidated hcDNA through a quality-by-design approach.
Good for people, good for planet
Stable cell lines aren’t just good for patients. They’re helpful for the planet too. Stable cell lines streamline upstream manufacturing by eliminating the requirement for transfection reagents or plasmids, thereby reducing the number of raw materials necessary for viral vector production when compared to large-scale transient transfection.
Abate says: “We now offer end-to-end solutions for viral vector manufacturing. With our new cell line offering, our customers can deliver higher quality treatments and significantly improve patient access today as well as meet the increasing demand for viral vector material tomorrow.”
Take a deeper dive into the smart, savvy science driving viral vector scale up.
Want more info on the cell lines? Click here.
If you’re at ASGCT in Baltimore, stop by Booth #1717 to chat with our team.
Cytiva, ELEVECTA and HyClone are trademarks of Global Life Sciences USA LLC or an affiliate doing business as Cytiva.
About Cytiva
At Cytiva, our mission is to advance and accelerate the development of therapeutics. With 15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers. Learn more at cytiva.com.
Media contact:
Tania Kimball